Group 1 - The company, Akeso Inc. (09939), experienced a significant decline of over 14%, trading at HKD 2.2 with a transaction volume of HKD 53.6885 million [1] - Akeso announced a placement of 20.673 million shares at a price of HKD 2.08 per share, representing an 18.75% discount from the previous closing price of HKD 2.56, with estimated net proceeds of approximately HKD 40.34 million [1] - The net proceeds from the placement will be used for general working capital and business purposes, resulting in a reduction of the shareholding of the company's co-founder and major shareholder, Tong Youzhi, from 11.19% to 10.69% [1] Group 2 - The company has completed the enrollment of 666 patients in the critical Phase III clinical trial for its self-developed potential first-in-class KX-826 topical solution for hair loss [1] - The Phase II portion of the trial has met its primary endpoint with statistically significant and clinically meaningful results, demonstrating both efficacy and safety [1] - The company cannot ensure the successful development and eventual commercialization of KX-826 or other products beyond the KX-826 topical solution and acne cream [1]

智通财经APP获悉，开拓药业-B(09939)重挫逾14%，截至发稿，跌14.06%，报2.2港元，成交额5368.85 万港元。 此外，开拓药业自主研发、潜在同类首创的KX-826酊1.0%治疗脱发的关键性临床试验III期阶段已完成 全部666名患者入组。该项关键性临床试验采用II/III期操作无缝衔接设计，II期阶段已达到主要研究终 点，结果具有统计学显着性及临床意义，且有效性和安全性均表现出色。除826外用防脱液和祛痘膏等 化妆品产品和化妆品原料外，本公司无法确保将能成功开发及最终成功销售KX-826的其他产品。本公 司股东及潜在投资者在买卖本公司股份时务请审慎行事。 消息面上，开拓药业宣布，拟通过先旧后新方式配售2067.3万股股份，每股配售价2.08港元，较上一日 收盘价2.56港元折让18.75%，所得款项净额估计约为4034万港元。公司拟将认购事项所得款项净额用于 集团的一般营运资金及一般业务。紧随完成后，公司联合创始人、董事会主席、执行董事、行政总裁及 主要股东童友之于公司持股由11.19%降至10.69%。 ...

开拓药业-B(09939)重挫逾14%，截至发稿，跌14.06%，报2.2港元，成交额5368.85万港元。 此外，开拓药业自主研发、潜在同类首创的KX-826酊1.0%治疗脱发的关键性临床试验III期阶段已完成 全部666名患者入组。该项关键性临床试验采用II/III期操作无缝衔接设计，II期阶段已达到主要研究终 点，结果具有统计学显着性及临床意义，且有效性和安全性均表现出色。除826外用防脱液和祛痘膏等 化妆品产品和化妆品原料外，本公司无法确保将能成功开发及最终成功销售KX-826的其他产品。本公 司股东及潜在投资者在买卖本公司股份时务请审慎行事。 消息面上，开拓药业宣布，拟通过先旧后新方式配售2067.3万股股份，每股配售价2.08港元，较上一日 收盘价2.56港元折让18.75%，所得款项净额估计约为4034万港元。公司拟将认购事项所得款项净额用于 集团的一般营运资金及一般业务。紧随完成后，公司联合创始人、董事会主席、执行董事、行政总裁及 主要股东童友之于公司持股由11.19%降至10.69%。 ...

Core Viewpoint - The article discusses the transfer of shares of Innovent Biologics (09939) from Futu Securities International Hong Kong to BOC International Securities, with a total market value of HKD 124 million, representing 11.04% of the shares [1] Group 1: Share Transfer and Agreement - On July 31, shareholders of Innovent Biologics transferred shares valued at HKD 124 million to BOC International Securities, accounting for 11.04% of the total shares [1] - Innovent Biologics announced an agreement with Dr. Tong Youzhi and the seller (KT International Investment Limited) to sell 20.673 million shares at a price of HKD 2.08 per share, which is approximately 4.62% of the company's issued share capital [1] Group 2: Fundraising Purpose - The placement and subscription are aimed at supplementing the long-term funding for the group's general business and growth strategy [1] - The net proceeds from the subscription are estimated to be approximately HKD 40.34 million after deducting related expenses, which will be used for general working capital and business operations [1]

香港联交所最新资料显示，7月31日，开拓药业-B(09939)股东将股票由富途证券国际香港转入中银国际 证券，转仓市值1.24亿港元，占比11.04%。 进行配售事项及认购事项旨在补充集团的一般业务及增长策略的长期资金。董事认为，配售事项及认购 事项亦将为公司提供进一步集资的机会，同时扩大公司的股东基础及资本基础。经扣除相关费用及开支 后，认购事项的所得款项净额估计约为4034万港元。公司拟将认购事项所得款项净额用于集团的一般营 运资金及一般业务。 开拓药业发布公告，2025年8月1日(交易时段前)，公司、童友之博士及卖方(即KT International Investment Limited，由童博士全资拥有)与配售代理(即中银国际)订立该协议，据此，(i)卖方同意出售而 配售代理同意(作为卖方的代理)尽最大努力促使买方按每股股份2.08港元的价格购买卖方持有的合共 2067.3万股股份，相当于公司于本公告日期的已发行股本约4.62%；及(ii)卖方有条件同意作为委托人按 认购价(相当于配售价每股股份2.08港元)认购而公司有条件同意发行2067.3万股新股份(即认购股份)。 ...

Group 1 - The company, together with Tong Youzhi, has signed an agreement with the seller KT International Investment Limited for the sale of 20.673 million shares, representing approximately 4.62% of the issued share capital, at a price of HKD 2.08 per share [2] - The seller will also subscribe for new shares of the company at the same price of HKD 2.08 per share, with the same quantity of 20.673 million shares [2] - The placement and subscription will account for approximately 4.42% of the company's enlarged issued share capital, with the subscription price reflecting a discount of about 18.75% compared to the closing price of HKD 2.56 on July 31, 2025 [2] - The expected net proceeds from the subscription are approximately HKD 40.34 million, which the company plans to use for general working capital and business operations [2]

Core Viewpoint - The company, Akeso Inc. (09939), announced a share placement agreement involving the sale of 20.673 million shares at a price of HKD 2.08 per share, representing approximately 4.62% of the company's issued share capital as of the announcement date [1] Group 1 - The seller, KT International Investment Limited, agrees to sell 20.673 million shares, and the placement agent will use its best efforts to facilitate the purchase by buyers at the specified price [1] - The placement price of HKD 2.08 represents a discount of approximately 18.75% compared to the closing price of HKD 2.56 on July 31, 2025 [1] - The estimated net proceeds from the placement are approximately HKD 40.34 million, which will be used for general working capital and business purposes [1] Group 2 - The placement agent has conditionally agreed to act on behalf of the seller to place the shares, which will represent about 4.42% of the company's issued share capital after the placement, assuming no changes in the issued share capital until completion [1] - The company has conditionally agreed to issue 20.673 million new shares at the subscription price, which is the same as the placement price [1]

开拓药业-B(09939)发布公告，于2025年8月1日(交易时段前)，公司、童友之及卖方(KT International Investment Limited)与配售代理订立该协议，据此，(i)卖方同意出售而配售代理同意(作为卖方的代理)尽 最大努力促使买方按每股股份2.08港元的价格购买卖方持有的合共2067.3万股股份，相当于公司于本公 告日期的已发行股本约4.62%;及(ii)卖方有条件同意作为委托人按认购价(相当于配售价每股股份2.08港 元)认购而公司有条件同意发行2067.3万股新股份(即认购股份)。 配售代理有条件同意作为卖方的代理尽最大努力配售2067.3万股股份，相当于经认购事项扩大后的公司 已发行股本约4.42%(假设除发行认购股份外，公司已发行股本自本公告日期起至认购事项完成止并无变 动)。配售价/认购价2.08港元较：股份于2025年7月31日在联交所所报的收市价每股2.56港元折让约 18.75%。 认购事项的所得款项净额估计约为4034万港元(已扣除相关费用及开支)。公司拟将认购事项全部所得款 项净额用于集团一般营运资金及一般业务。 ...

Group 1 - The core point of the article is that 开拓药业 (stock code: 9939) announced a financing plan through the placement of existing shares and subscription for new shares, raising approximately HKD 40.34 million [1] - The financing involves the placement of 20,673,000 shares at a price of HKD 2.08 per share, which represents a discount of about 18.8% compared to the last closing price of HKD 2.56 [1] - The shares being placed account for approximately 4.6% of the existing issued share capital and will represent about 4.4% of the enlarged share capital after completion [1] Group 2 - The funds raised will be used for general working capital and business operations of the company [1] - The financing is conducted under a general mandate granted by the shareholders' meeting and is expected to be completed within 14 days from the agreement date or at another time agreed upon by the company, seller, and placement agent [1]

Group 1 - The company, Akeso, announced a placement of 20.7 million shares at a price of HKD 2.08 per share on the Hong Kong Stock Exchange [1]